BACKGROUND: Identification of correlates of protection against human influenza A virus infection is important in development of broadly protective ("universal") influenza vaccines. Certain assumptions underlie current vaccine developmental strategies, including that infection with a particular influenza A virus should offer long-term or lifelong protection against that strain, preventing reinfection. In this study we report observations made when 7 volunteers participated in sequential influenza challenge studies where they were challenged intranasally using the identical influenza A(H1N1)pdm09 virus approximately 1 year apart. We evaluate and describe the outcomes of these 7 rechallenge participants and discuss what these results may suggest about correlates of protection and development of more broadly protective influenza vaccines. METHODS: Seven participants were enrolled in 2 viral challenge studies at 7.5- to 18.5-month intervals. Both challenge studies used the identical lot of influenza A (H1N1)pdm09 virus administered intranasally. We evaluated pre- and postchallenge hemagglutination inhibition, neuraminidase inhibition, and stalk antibody titers; peripheral blood leukocyte host gene expression response profiles; daily viral detection via nasal wash; and clinical signs and symptoms. RESULTS: At least 3 of 7 participants demonstrated confirmed laboratory evidence of sequential infection, with 5 of 7 demonstrating clinical evidence. CONCLUSIONS: The data presented in this report demonstrate that sequential infection with the identical influenza A virus can occur and suggest it may not be rare. These data raise questions about immune memory responses in an acute superficial respiratory mucosal infection and their implications in development of broadly protective influenza vaccines. Further investigation of these observations is warranted. CLINICAL TRIALS REGISTRATION: NCT01646138; NCT01971255. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
BACKGROUND: Identification of correlates of protection against humaninfluenza A virus infection is important in development of broadly protective ("universal") influenza vaccines. Certain assumptions underlie current vaccine developmental strategies, including that infection with a particular influenza A virus should offer long-term or lifelong protection against that strain, preventing reinfection. In this study we report observations made when 7 volunteers participated in sequential influenza challenge studies where they were challenged intranasally using the identical influenza A(H1N1)pdm09 virus approximately 1 year apart. We evaluate and describe the outcomes of these 7 rechallenge participants and discuss what these results may suggest about correlates of protection and development of more broadly protective influenza vaccines. METHODS: Seven participants were enrolled in 2 viral challenge studies at 7.5- to 18.5-month intervals. Both challenge studies used the identical lot of influenza A (H1N1)pdm09 virus administered intranasally. We evaluated pre- and postchallenge hemagglutination inhibition, neuraminidase inhibition, and stalk antibody titers; peripheral blood leukocyte host gene expression response profiles; daily viral detection via nasal wash; and clinical signs and symptoms. RESULTS: At least 3 of 7 participants demonstrated confirmed laboratory evidence of sequential infection, with 5 of 7 demonstrating clinical evidence. CONCLUSIONS: The data presented in this report demonstrate that sequential infection with the identical influenza A virus can occur and suggest it may not be rare. These data raise questions about immune memory responses in an acute superficial respiratory mucosal infection and their implications in development of broadly protective influenza vaccines. Further investigation of these observations is warranted. CLINICAL TRIALS REGISTRATION: NCT01646138; NCT01971255. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Authors: Matthew J Memoli; Lindsay Czajkowski; Susan Reed; Rani Athota; Tyler Bristol; Kathleen Proudfoot; Sarah Fargis; Matthew Stein; Rebecca L Dunfee; Pamela A Shaw; Richard T Davey; Jeffery K Taubenberger Journal: Clin Infect Dis Date: 2014-11-20 Impact factor: 9.079
Authors: Suzanne E Ohmit; Joshua G Petrie; Rachel T Cross; Emileigh Johnson; Arnold S Monto Journal: J Infect Dis Date: 2011-10-12 Impact factor: 5.226
Authors: Timothy D Carroll; Shannon R Matzinger; Linda Fritts; Michael B McChesney; Christopher J Miller Journal: PLoS One Date: 2011-06-29 Impact factor: 3.240
Authors: Anton Camacho; Sébastien Ballesteros; Andrea L Graham; Fabrice Carrat; Oliver Ratmann; Bernard Cazelles Journal: Proc Biol Sci Date: 2011-04-27 Impact factor: 5.349
Authors: Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores Journal: Clin Microbiol Rev Date: 2022-07-06 Impact factor: 50.129
Authors: Maggie L Bartlett; San Suwanmanee; Nadine Peart Akindele; Shristi Ghimire; Andy K P Chan; Chenxu Guo; Stephen J Gould; Andrea L Cox; Diane E Griffin Journal: Viral Immunol Date: 2022-03-14 Impact factor: 2.175
Authors: David S Khoury; Deborah Cromer; Arnold Reynaldi; Timothy E Schlub; Adam K Wheatley; Jennifer A Juno; Kanta Subbarao; Stephen J Kent; James A Triccas; Miles P Davenport Journal: Nat Med Date: 2021-05-17 Impact factor: 87.241
Authors: Muhammad Moazzam; Muhammad Imran Sajid; Hamza Shahid; Jahanzaib Butt; Irfan Bashir; Muhammad Jamshaid; Amir Nasrolahi Shirazi; Rakesh Kumar Tiwari Journal: Int J Environ Res Public Health Date: 2020-08-14 Impact factor: 3.390
Authors: Deborah Cromer; Jennifer A Juno; Stephen J Kent; Miles P Davenport; David Khoury; Arnold Reynaldi; Adam K Wheatley Journal: Nat Rev Immunol Date: 2021-04-29 Impact factor: 53.106